99-4764. Cumulative List of Orphan Drug and Biological Designations  

  • [Federal Register Volume 64, Number 38 (Friday, February 26, 1999)]
    [Notices]
    [Pages 9515-9516]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-4764]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    [Docket No. 84N-0102]
    
    
    Cumulative List of Orphan Drug and Biological Designations
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing the 
    availability of the cumulative list of orphan drug and biological 
    designations as of December 31, 1998. FDA has announced the 
    availability of previous lists, which are updated monthly, identifying 
    the drugs and biologicals granted orphan designation under the Federal 
    Food, Drug, and Cosmetic Act (the act).
    
    ADDRESSES: Copies of the cumulative list of orphan drug and biological 
    designations are available from the Dockets Management Branch (HFA-
    305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
    Rockville, MD 20852, and the Office of Orphan Products Development (HF-
    35), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 
    20857, 301-827-3666.
    
    FOR FURTHER INFORMATION CONTACT: Lisa M. Hubbard or Stephanie Donahoe, 
    Office of Orphan Products Development (HF-35), Food and Drug 
    Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-3666.
    
    SUPPLEMENTARY INFORMATION: FDA's Office of Orphan Products Development 
    (OPD) reviews and takes final action on applications submitted by 
    sponsors seeking orphan designation of their drug or biological under 
    section 526 of the act (21 U.S.C. 360bb). In accordance with this 
    section of the act which requires public notification of designations, 
    FDA maintains a cumulative list of orphan drug and biological 
    designations. This list includes the name of the drug or biological, 
    the specific disease/condition for which the drug or biological is 
    designated, and information about the sponsor such as the name, 
    address, telephone number, and contact.
         At the end of each calendar year, the agency publishes a 
    cumulative list of orphan drug and biological designations current 
    through the calendar year. The list that is the subject of this notice 
    is the cumulative list of orphan drug and biological designations 
    through December 31, 1998, and, therefore, brings the January 30, 1998 
    (63 FR 4644), publication up to date. This list is available upon 
    request from the Dockets Management Branch (address above). Those 
    requesting a copy should specify Docket No. 84N-0102, which is the 
    docket number for this notice. In addition, the list is updated monthly 
    and is available upon request from OPD or FDA's Dockets Management 
    Branch (address above). The current list is also available on the 
    website, http://www.fda.gov/orphan.
         The orphan designation of a drug or biological applies only to the 
    sponsor who requested the designation. Each sponsor interested in 
    developing a drug or biological for an orphan indication must apply for 
    orphan designation in order to obtain exclusive marketing rights. Any 
    request for designation must be received by FDA before the submission 
    of a marketing application for the proposed indication for which
    
    [[Page 9516]]
    
    designation is requested (21 CFR 316.23). Copies of the orphan drug 
    regulations (21 CFR part 316) (57 FR 62076, December 29, 1992) and 
    explanatory background materials for use in preparing an application 
    for orphan designation may be obtained from OPD (address above).
         The names of the drugs and biologicals shown in the cumulative 
    list of orphan designations may change upon marketing approval/
    licensing, reflecting the established, proper name approved by FDA. 
    Because drugs and biologicals not approved/licensed for marketing are 
    investigational, the appropriate established, proper name has not 
    necessarily been assigned.
    
        Dated: February 19, 1999.
     William K. Hubbard,
     Associate Commissioner for Policy Coordination.
    [FR Doc. 99-4764 Filed 2-25-99; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
02/26/1999
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
99-4764
Pages:
9515-9516 (2 pages)
Docket Numbers:
Docket No. 84N-0102
PDF File:
99-4764.pdf